In NLRP3 deal with Novo, Ventus fences off some indications for itself

Ventus has partnered with Novo to develop its preclinical NLRP3 inhibitor in certain indications the biotech believes are best suited to a pharma of that size, while retaining control of the program to treat diseases the biotech can pursue on its own.

The well-funded biotech will receive $70 million up front from Novo Nordisk A/S (CSE:NOVO B; NYSE:NVO) in a deal that allows the pharma to develop a set of peripherally restricted NLRP3 inhibitors, including lead molecule VENT-01, to treat a basket of indications including chronic kidney disease, non-alcoholic steatohepatitis (NASH), and cardiometabolic disorders such as atherosclerosis...